Market Overview

UPDATE: Bank of America Initiates Coverage on Myriad Genetics

Share:
Related MYGN
Worst Performing Industries For February 3, 2016
Myriad Genetics, Thermo Fisher Two Top Life Science & Diagnostic Picks At Deutsche Bank
Chuck Royce Reduces Several Positions in 4th Quarter (GuruFocus)

According to a research report published this morning, Bank of America has initiated Myriad Genetics (NASDAQ: MYGN) with a Neutral rating and $28 PT.

Bank of America said in the report, "We reinstate Myriad Genetics (MYGN), a leading molecular diagnostics company, with a Neutral rating and $28 price objective. While we are positive about Myriad's initiatives to bolster near-to-midterm sales, we have some reservations about Myriad's long-term growth as its flagship product, BRACAnalysis, matures."

Myriad Genetics closed yesterday at $25.75.

Latest Ratings for MYGN

DateFirmActionFromTo
Jan 2016Deutsche BankInitiates Coverage onBuy
Jan 2016Avondale PartnersInitiates Coverage onMarket Outperform
Dec 2015Goldman SachsUpgradesSellNeutral

View More Analyst Ratings for MYGN
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Initiation Analyst Ratings

 

Related Articles (MYGN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters